EPO Patents = 1

Forward Citations = 15

Loading Chart...

11 inventors (with patents filed for the assignee):

Dalia Megiddo (6 out of 16 patents)

Rina Yamin (5 out of 6 patents)

Yaron Ilan (3 out of 47 patents)

4. Yaron Daniely (3 out of 5 patents)

5. Shimon Amselem (2 out of 36 patents)

6. Gur Megiddo (2 out of 2 patents)

7. David Baker (1 out of 4 patents)

8. Hanna Ron (1 out of 3 patents)

9. David Siner (1 out of 3 patents)

10. Jonathan Rubin (1 out of 1 patent)

11. Johanna Schumann (1 out of 1 patent)

8 patents: Sort by Forward Citations

1. 9931303 - Abuse deterrent formulations of amphetamine (2018-04-03),

2. 9851355 - Methods of determining response to therapy (2017-12-26),

3. 9851354 - Methods of treating fragile X syndrome and related disorders (2017-12-26),

4. 9808446 - Method for decreasing symptoms of alcohol consumption (2017-11-07),

5. 9428458 - Substituted pyridoxine-lactam carboxylate-salts (2016-08-30),

6. 8889715 - Substituted pyridoxine-lactam carboxylate salts (2014-11-18),

7. 8710067 - Method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition (2014-04-29),

8. 8476304 - Method for decreasing symptoms of alcohol consumption (2013-07-02),

Alcobra Ltd. is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders. Their lead product candidate, MDX, is currently in clinical trials for the treatment of Fragile X Syndrome and ADHD. Alcobra is dedicated to improving the lives of patients through innovative therapies and research.

This text is generated by artificial intelligence and may not be accurate.